Ken Griffin Arrowhead Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $193,600 - $295,400	10,000 Added 14.01%	81,400 $1.58 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $387,099 - $499,848	17,700 Added 32.96%	71,400 $1.86 Million
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $21,768 - $31,583	800 Added 1.51%	53,700 $1.54 Million
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $400,680 - $586,467	18,900 Added 55.59%	52,900 $1.62 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $298,680 - $411,312	-11,400 Reduced 25.11%	34,000 $913,000
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $211,344 - $347,592	8,400 Added 22.7%	45,400 $1.62 Million
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $1.06 Million - $1.72 Million	-44,700 Reduced 54.71%	37,000 $939,000
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $137,200 - $198,744	-4,900 Reduced 5.66%	81,700 $3.31 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $11,852 - $19,324	400 Added 0.46%	86,600 $2.86 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.